Adverse events · people with Parkinson's disease
1 finding from 1 review
Economic outcomes · people with Parkinson's disease
1 finding from 1 review
Physician‐assessed changes in clinical signs · atopic eczema
1 finding from 1 review
Patient‐reported changes in symptoms ‐ not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
Investigator Global Assessment ‐ not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
Health‐related quality of life ‐ not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events not measured · atopic eczema
The review found no eligible studies for this question.
1 finding from 1 review
Hypoglycemia: number of episodes · adults with CFRD
It is very uncertain whether summary of findings: repaglinide changes hypoglycemia: number of episodes compared with placebo (very low certainty).
1 finding from 1 review
HbA1c (glycated haemoglobin), change · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in hbA1c (%) change from baseline compared with insulin (high certainty).
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in FEV1 % predicted change from baseline compared with insulin (moderate certainty).
1 finding from 1 review
FVC (% predicted) Change from baseline · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in FVC % predicted change from baseline compared with insulin (moderate certainty).
1 finding from 1 review
Change in BMI · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in BMI (kg/m²) change from baseline compared with insulin (low certainty).
1 finding from 1 review
Hypoglycemia: number of episodes · children over 12 and adults with CFRD
Summary of findings: repaglinide showed no clear difference in hypoglycemia number of episodes compared with insulin (low certainty).
1 finding from 1 review
HbA1c (%) · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FVC · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Body‐mass index (BMI) · adults with CFRD and fasting hyperglycemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Hypoglycemia mean number of events per participant · adults with CFRD and fasting hyperglycemia
It is very uncertain whether summary of findings: NPH insulin changes hypoglycemia mean number of events per participant compared with glargine (very low certainty).
1 finding from 1 review
HbA1c (%) · adults with CFRD
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults with CFRD
Summary of findings: repaglinide showed no clear difference in FEV1 % predicted; change from baseline compared with placebo (low certainty).
1 finding from 1 review